In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.

AUTOR(ES)

Tanio, T

RESUMO

SM-8668 (Sch 39304) is a new oral antifungal agent which we evaluated in comparison with fluconazole in various fungal infection models. The prophylactic effect of SM-8668 was excellent against systemic candidiasis, aspergillosis, and cryptococcosis in mice. The 50% effective dose for SM-8668 was assessed at 10 days after infection and was 0.18, 3.7, and 5.9 mg/kg (body weight), respectively, for the above-mentioned fungal diseases. Fluconazole was about four times less effective than SM-8668 against systemic candidiasis and was only slightly effective at doses of 80 and 25 mg/kg against systemic aspergilosis and cryptococcosis, respectively. SM-8668 was also about four to eight times more active than fluconazole against vaginal candidiasis in rats and against dermatophytic infection in guinea pigs. In addition, topical SM-8668 was as effective as topical miconazole or tioconazole against skin mycosis in guinea pigs. After oral administration, SM-8668 showed a maximum concentration in serum similar to that of fluconazole in both mice and rats, but the elimination half-life and area under the serum concentration-time curve for SM-8668 were twice those for fluconazole.

Documentos Relacionados

• Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
• In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.
• In vitro and in vivo antifungal activities of D0870, a new triazole agent.
• Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.
• Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent.